/ /

  • linkedin
  • Increase Font
  • Sharebar

    Cyclosporine for dry eye associated with anti-PD-1 therapy

    Case demonstrates critical ophthalmic role in cancer patients

    History

    A 58-year-old man with metastatic melanoma from a primary nasal sinus tumor was referred to ophthalmology for bilateral eye irritation. Around this time, he was undergoing his sixth cycle of nivolumab (3 mg/kg) for treatment of metastatic melanoma. His metastatic lesions had been regressing favorably in response to nivolumab, an immunomodulatory agent that upregulates host immunity. The patient was assessed to have dry eye syndrome for which he was started on preservative-free artificial tears and lubricating ointment at bedtime. For the next two weeks, he continued to experience persistent burning in both eyes and was then referred to a cornea specialist. 

    Examination

    On presentation to the Cornea Service, his corrected visual acuity was 20/30 in the right eye and 20/25 in the left. His examination was notable for a low tear meniscus and diffusely distributed punctate epithelial erosions in both eyes. A basic secretion test (Schirmer’s with anesthesia) was performed which yielded values less than 4.0 mm from each eye.

    Treatment and Clinical Course

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results